Pacira BioSciences (PCRX) has an average rating of outperform and price targets ranging from $54 to $85, according to analysts polled by Capital IQ. (MT...
Pacira BioSciences (PCRX) said Friday that the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Exparel...
Pacira BioSciences (PCRX) and surgical cost management company IPG have signed a a collaboration deal intended to reduce postsurgical opioid prescribing...
On Sep 09, 2020, Director, Dr Andreas Wicki, executed a sale of 2,216 shares in Pacira Biosciences (PCRX) for $137,436. Dr Wicki, subsequent to the...
| Address | 5 Sylvan Way Parsippany, New Jersey 07054 |
| Phone | +1.973.254.3560 |
| Number of Employees | 518 |
| Recent SEC Filing | 09/21/2020 4 |
| Chairman, Chief Executive & Operating Officer | David M. Stack |
| Chief Financial Officer | Charles A. Reinhart |
| Vice President-Research & Development | Vladimir Kharitonov |
| Chief Technology Officer | Charles Anthony Laranjeira |
| Price Open | $59.61 |
| Previous Close | $59.37 |
| 52 Week Range | $27.46 - 64.44 |
| Market Capitalization | $2.5 B |
| Shares Outstanding | 42.7 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Other | Next Earnings Announcement | 11/05/2020 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | $0.09 |
| Beta vs. S&P 500 | N/A |
| Revenue | $337.3 M |
| Net Profit Margin | -2.47% |
| Return on Equity | -2.76% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
